Teal Health has launched general availability of its Teal Wand at-home cervical cancer screening kit in California. The FDA-authorized self-collection tool for at-home cervical cancer screening is now available for the first time to consumers in the United States.
The launch follows FDA authorization in May 2025 and addresses a waitlist of over 32,000 women who registered interest in the product. The at-home screening kit is available through insurance coverage, direct payment, or HSA/FSA accounts via the company’s website.
The Teal Wand is prescribed for individuals at average risk according to national screening guidelines, offering an alternative to traditional in-office Pap smears that many women find inconvenient or uncomfortable. It enables women to collect their own cervical samples at home, which are then tested for HPV using the same cobas HPV test from Roche that is recommended by medical guidelines for cervical cancer screening. The service includes virtual telehealth consultations with Teal Medical providers who prescribe the kit, review lab results, and coordinate follow-up care when needed.
Clinical trial data showed 94% of women preferred the Teal Wand to standard office-based screening. Early users have given the service an average satisfaction rating of 4.95 out of 5 stars, with feedback highlighting convenience and ease of use.
“Women have been so receptive to using the Teal Wand to collect their own sample from home,” said Dr. Liz Swenson, OBGYN and Medical Director of the Teal Medical Practice. “We have even seen a large number of women who are well into their screening years, but have never screened.”
The device targets an underserved population, with over 50% of early Teal users being underscreened or never previously screened for cervical cancer. Nearly one in three women in the United States are not up to date on cervical cancer screening, despite guidelines recommending screening for ages 25-65.
“Teal is a much preferred screening alternative, and we are poised to make a sizable impact on screening rates in the U.S.,” said Kara Egan, CEO and Co-Founder of Teal Health. “Our goal from day one has been to get Teal into the hands of women as quickly as possible after FDA-authorization.”
The company now plans to expand to additional states and achieve U.S.-wide availability before the end of 2026.
